The heart in rheumatoid arthritis: Difference between revisions

Jump to navigation Jump to search
No edit summary
Line 30: Line 30:
Myocarditis can take the form of either a granulomatous disease or interstitial myocarditis.  Granulomatous involvement of the heart is localized and is specific for the rheumatoid involvement of the heart. Myocarditis, in contrast, involves not localized but diffuse infiltration of the myocardium by mononuclear cells, may involve the entire myocardium and yet have no clinical manifestations.<ref name="pmid2724254">{{cite journal |vauthors=Sigal LH, Friedman HD |title=Rheumatoid pancarditis in a patient with well-controlled rheumatoid arthritis |journal=J. Rheumatol. |volume=16 |issue=3 |pages=368–73 |date=March 1989 |pmid=2724254 |doi= |url=}}</ref>
Myocarditis can take the form of either a granulomatous disease or interstitial myocarditis.  Granulomatous involvement of the heart is localized and is specific for the rheumatoid involvement of the heart. Myocarditis, in contrast, involves not localized but diffuse infiltration of the myocardium by mononuclear cells, may involve the entire myocardium and yet have no clinical manifestations.<ref name="pmid2724254">{{cite journal |vauthors=Sigal LH, Friedman HD |title=Rheumatoid pancarditis in a patient with well-controlled rheumatoid arthritis |journal=J. Rheumatol. |volume=16 |issue=3 |pages=368–73 |date=March 1989 |pmid=2724254 |doi= |url=}}</ref>


==Amyloidosis==
==Nodules==
Amyloidosis in RA has been reported in numerous case-series studies to be present in a high variation of frequency, probably due to patients’ selection. <ref>Wiland P, Wojtala R, Goodacre J, Szechinski J. The prevalence of subclinical amyloidosis in Polish patients with rheumatoid arthritis. Clin Rheumatol 2004;23:193–98.</ref> Amyloidosis occurs preferentially in male patients with a longer disease duration. The relevance of cardiac involvement including cardiac amyloidosis is illustrated by the high frequency of cardiac failure as a cause of mortality in RA patients treated with hemodialysis <ref>Kuroda T, Tanabe N, Harada T et al. Long-term mortality outcome in patients with reactive amyloidosis associated with rheumatoid arthritis. Clin Rheumatol 2005;3:1–8.</ref>. Intensified immunosuppressive treatment should be considered if a RA patient is diagnosed with amyloidosis.
Rheumatoid nodules are formed in the different parts of the heart such pericardium, myocardium, and valvular structures. Nodules can lead to different kind of symptoms depending upon the location of nodules such as syncope and conduction defects.<ref name="pmid6882034">{{cite journal |vauthors=Ahern M, Lever JV, Cosh J |title=Complete heart block in rheumatoid arthritis |journal=Ann. Rheum. Dis. |volume=42 |issue=4 |pages=389–97 |date=August 1983 |pmid=6882034 |pmc=1001249 |doi= |url=}}</ref>
 
==Diagnosis of cardiac disease in rheumatoid arthritis==
 


==Endocardial Inflammation==
Echocardiographic studies have reported evidence of previously unrecognized [[mitral valve]] disease diagnosed by a reduced E-F slope of the anterior leaflet of the [[mitral valve]]. Although [[aortic valve]] disease and arthritis are generally associated through [[ankylosing spondylitis]], a number of patients with granulomatous nodules on the valve have been reported <ref>Iveson JM, Thadani U, Ionescu M, et al: Aortic valve incompetence and replacement in rheumatoid arthritis. Ann Rheum Dis  1975; 34:312-320.</ref>
===Management of conduction disturbances in rheumatic diseases===
===Management of conduction disturbances in rheumatic diseases===
[[Pacemaker]] implantation is the method of choice for the treatment of [[complete heart block]] and other serious conduction abnormalities. Sophisticated pacing modalities and programmability as well as low-energy circuitry and new battery designs have increased device longevity and enabled wide clinical application. A simple VVI pacemaker (paces and senses the ventricle and is inhibited by a sensed ventricular event) may be adequate for transient or infrequent bradyarrhythmia. For frequent or persistent bradyarrhythmia, prolonged dependence on ventricular pacing may warrant use of a rate-responsive demand unit or, if no atrial or sinus node abnormalities are present, a dual-chamber system (DDD—both chambers are capable of being sensed and paced). New devices enable resynchronization therapy in patients with [[dilated cardiomyopathy]] and severely impaired contractility, with beneficial effect on haemodynamics and long-term survival.  
[[Pacemaker]] implantation is the method of choice for the treatment of [[complete heart block]] and other serious conduction abnormalities. Sophisticated pacing modalities and programmability as well as low-energy circuitry and new battery designs have increased device longevity and enabled wide clinical application. A simple VVI pacemaker (paces and senses the ventricle and is inhibited by a sensed ventricular event) may be adequate for transient or infrequent bradyarrhythmia. For frequent or persistent bradyarrhythmia, prolonged dependence on ventricular pacing may warrant use of a rate-responsive demand unit or, if no atrial or sinus node abnormalities are present, a dual-chamber system (DDD—both chambers are capable of being sensed and paced). New devices enable resynchronization therapy in patients with [[dilated cardiomyopathy]] and severely impaired contractility, with beneficial effect on haemodynamics and long-term survival.  

Revision as of 14:33, 26 April 2018

WikiDoc Resources for The heart in rheumatoid arthritis

Articles

Most recent articles on The heart in rheumatoid arthritis

Most cited articles on The heart in rheumatoid arthritis

Review articles on The heart in rheumatoid arthritis

Articles on The heart in rheumatoid arthritis in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on The heart in rheumatoid arthritis

Images of The heart in rheumatoid arthritis

Photos of The heart in rheumatoid arthritis

Podcasts & MP3s on The heart in rheumatoid arthritis

Videos on The heart in rheumatoid arthritis

Evidence Based Medicine

Cochrane Collaboration on The heart in rheumatoid arthritis

Bandolier on The heart in rheumatoid arthritis

TRIP on The heart in rheumatoid arthritis

Clinical Trials

Ongoing Trials on The heart in rheumatoid arthritis at Clinical Trials.gov

Trial results on The heart in rheumatoid arthritis

Clinical Trials on The heart in rheumatoid arthritis at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on The heart in rheumatoid arthritis

NICE Guidance on The heart in rheumatoid arthritis

NHS PRODIGY Guidance

FDA on The heart in rheumatoid arthritis

CDC on The heart in rheumatoid arthritis

Books

Books on The heart in rheumatoid arthritis

News

The heart in rheumatoid arthritis in the news

Be alerted to news on The heart in rheumatoid arthritis

News trends on The heart in rheumatoid arthritis

Commentary

Blogs on The heart in rheumatoid arthritis

Definitions

Definitions of The heart in rheumatoid arthritis

Patient Resources / Community

Patient resources on The heart in rheumatoid arthritis

Discussion groups on The heart in rheumatoid arthritis

Patient Handouts on The heart in rheumatoid arthritis

Directions to Hospitals Treating The heart in rheumatoid arthritis

Risk calculators and risk factors for The heart in rheumatoid arthritis

Healthcare Provider Resources

Symptoms of The heart in rheumatoid arthritis

Causes & Risk Factors for The heart in rheumatoid arthritis

Diagnostic studies for The heart in rheumatoid arthritis

Treatment of The heart in rheumatoid arthritis

Continuing Medical Education (CME)

CME Programs on The heart in rheumatoid arthritis

International

The heart in rheumatoid arthritis en Espanol

The heart in rheumatoid arthritis en Francais

Business

The heart in rheumatoid arthritis in the Marketplace

Patents on The heart in rheumatoid arthritis

Experimental / Informatics

List of terms related to The heart in rheumatoid arthritis

To review the complete article on rheumatoid arthritis, click here.

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Manpreet Kaur, MD [2]

Overview

People with rheumatoid arthritis are more prone to atherosclerosis, and risk of myocardial infarction and stroke is markedly increased.[6] Other possible complications that may arise include: pericarditis, endocarditis, left ventricular failure, valvulitis and fibrosis.[1] Cardiac disease with rheumatoid arthritis can be related to granulomatous proliferation or vasculitis. Echocardiography has made diagnosing pericarditis and endocardial inflammation easier.

Various cardiac complications of rheumatoid arthritis are discussed below:

The cardiac complications in rheumatoid arthritis are due to involvement by rheumatoid nodulosis. There is increased risk of coronary atherosclerosis and thereby increasing the risk of heart failure and atrial fibrillation. Various cardiac complications include:

Coronary artery disease

There is increased risk of coronary artery disease in rheumatoid arthritis. It could be due to chronic inflammation caused by cytokines, lymphocytes, macrophages, and dendritic cells. Other factors responsible are coagulation abnormalities, immune complexes, and oxidative stress.[2][3][4]

Heart failure

The risk of heart failure is relatively more common in patient with coronary artery disease in rheumatoid arthritis. This is caused by left ventricular dysfunction, inflammatory mediators, and antirheumatic drugs.[5][2]

Atrial fibrillation

The risk of atrial fibrillation is common in patients with heart failure and coronary artery disease in rheumatoid arthritis.[6]

Aortic insuuficiency

RA rarely causes symptomatic AR, but can as a result of granulomatous nodules that may form on the aortic leaflets.[7]

Pericarditis

Pericarditis is common in active rheumatoid arthritis. Symptomatic patients have RA factor positive.[8]

Myocarditis

Myocarditis can take the form of either a granulomatous disease or interstitial myocarditis. Granulomatous involvement of the heart is localized and is specific for the rheumatoid involvement of the heart. Myocarditis, in contrast, involves not localized but diffuse infiltration of the myocardium by mononuclear cells, may involve the entire myocardium and yet have no clinical manifestations.[9]

Nodules

Rheumatoid nodules are formed in the different parts of the heart such pericardium, myocardium, and valvular structures. Nodules can lead to different kind of symptoms depending upon the location of nodules such as syncope and conduction defects.[10]

Diagnosis of cardiac disease in rheumatoid arthritis

Management of conduction disturbances in rheumatic diseases

Pacemaker implantation is the method of choice for the treatment of complete heart block and other serious conduction abnormalities. Sophisticated pacing modalities and programmability as well as low-energy circuitry and new battery designs have increased device longevity and enabled wide clinical application. A simple VVI pacemaker (paces and senses the ventricle and is inhibited by a sensed ventricular event) may be adequate for transient or infrequent bradyarrhythmia. For frequent or persistent bradyarrhythmia, prolonged dependence on ventricular pacing may warrant use of a rate-responsive demand unit or, if no atrial or sinus node abnormalities are present, a dual-chamber system (DDD—both chambers are capable of being sensed and paced). New devices enable resynchronization therapy in patients with dilated cardiomyopathy and severely impaired contractility, with beneficial effect on haemodynamics and long-term survival.

References

  1. Wolfe F, Mitchell DM, Sibley JT; et al. (1994). "The mortality of rheumatoid arthritis". Arthritis Rheum. 37 (4): 481–94. PMID 8147925. Unknown parameter |month= ignored (help)
  2. 2.0 2.1 Van Doornum S, McColl G, Wicks IP (April 2002). "Accelerated atherosclerosis: an extraarticular feature of rheumatoid arthritis?". Arthritis Rheum. 46 (4): 862–73. PMID 11953961.
  3. Wållberg-Jonsson S, Cvetkovic JT, Sundqvist KG, Lefvert AK, Rantapää-Dahlqvist S (May 2002). "Activation of the immune system and inflammatory activity in relation to markers of atherothrombotic disease and atherosclerosis in rheumatoid arthritis". J. Rheumatol. 29 (5): 875–82. PMID 12022343.
  4. Wållberg-Jonsson S, Cederfelt M, Rantapää Dahlqvist S (January 2000). "Hemostatic factors and cardiovascular disease in active rheumatoid arthritis: an 8 year followup study". J. Rheumatol. 27 (1): 71–5. PMID 10648020.
  5. Schau T, Gottwald M, Arbach O, Seifert M, Schöpp M, Neuß M, Butter C, Zänker M (November 2015). "Increased Prevalence of Diastolic Heart Failure in Patients with Rheumatoid Arthritis Correlates with Active Disease, but Not with Treatment Type". J. Rheumatol. 42 (11): 2029–37. doi:10.3899/jrheum.141647. PMID 26373561.
  6. Lindhardsen J, Ahlehoff O, Gislason GH, Madsen OR, Olesen JB, Svendsen JH, Torp-Pedersen C, Hansen PR (March 2012). "Risk of atrial fibrillation and stroke in rheumatoid arthritis: Danish nationwide cohort study". BMJ. 344: e1257. PMC 3297675. PMID 22403267.
  7. Chand EM, Freant LJ, Rubin JW. Aortic valve rheumatoid nodules producing clinical aortic regurgitation and a review of the literature. Cardiovasc Pathol. Nov-Dec 1999;8(6):333-8.
  8. name="pmid11324775">Guedes C, Bianchi-Fior P, Cormier B, Barthelemy B, Rat AC, Boissier MC (April 2001). "Cardiac manifestations of rheumatoid arthritis: a case-control transesophageal echocardiography study in 30 patients". Arthritis Rheum. 45 (2): 129–35. doi:10.1002/1529-0131(200104)45:2<129::AID-ANR164>3.0.CO;2-K. PMID 11324775.
  9. Sigal LH, Friedman HD (March 1989). "Rheumatoid pancarditis in a patient with well-controlled rheumatoid arthritis". J. Rheumatol. 16 (3): 368–73. PMID 2724254.
  10. Ahern M, Lever JV, Cosh J (August 1983). "Complete heart block in rheumatoid arthritis". Ann. Rheum. Dis. 42 (4): 389–97. PMC 1001249. PMID 6882034.

Template:WH Template:WS